

Table of Contents

| Introduction | 2 |
|--|----|
| Background/Summary | 2 |
| Purpose of the Tool | 2 |
| Using the Diabetes Tool in OSCAR Pro | 3 |
| Getting Started with the Diabetes Tool | 4 |
| Tool Design | 5 |
| Patient Summary Dashboard | 5 |
| Launching Clinical Modules | 6 |
| Clinical Assessment Module | 6 |
| Management Module | 7 |
| Medication Module | 8 |
| Patient Care Plan Module | 9 |
| Feedback | 10 |
| Overview of Usage Analytics | 10 |
| Contact | 11 |
| Appendix | 12 |
| Quality Standards for Diabetes | 12 |



Evidence2Practice - Diabetes Tool v. 1.0.0 - User Guide

Introduction

The Evidence2Practice Ontario (E2P) diabetes tool is designed to support clinicians in early identification, comprehensive assessment, and timely diagnostic clarifications, using digitally embedded validated tools for prediabetes and type 2 diabetes. Each E2P tool contains condition-specific modules (scalable to multiple conditions) based on the core clinical functions of the quality standards. These modules include Clinical Assessment, Medication, Management, and Patient Care Plan and Resources.

This guide provides a walk-through of our diabetes tool with examples, highlighting the most important functionalities.

Background/Summary

In 2019, an estimated 4.4 million Ontarians were living with prediabetes and diabetes (type 1 diabetes, diagnosed and undiagnosed type 2 diabetes, and prediabetes combined). Roughly 90% of all cases of diabetes are type 2 diabetes. People with diabetes are at risk of developing serious, acute complications which include severe hypoglycemia, long-term microvascular complications affecting the eyes, kidneys, and nerves, and cardiovascular disease.

The factors that increase the risk of type 2 diabetes are multifaceted and can be social as well as genetic/biological. Certain populations experience higher rates of type 2 diabetes, such as those with low income, people of African, Arab, South Asian, or Hispanic descent, and Indigenous populations. In Ontario, the prevalence of self-reported diabetes is roughly twice as high for South Asian people (8.1%) and Black people (8.5%) as it is for White people (4.2%). Indigenous populations are three to five times more likely to have type 2 diabetes than non-Indigenous Canadians (Ontario Health, – Care for People of All Ages, 2023).

Purpose of the Tool

The objective was to create an EMR-integrated tool that supports clinicians in the screening and management of diabetes. The E2P diabetes tool for OSCAR Pro supports a more comprehensive picture of the different steps involved in diabetes care: clinical assessment, pharmacologic and nonpharmacologic treatment goals, shared decision-making, selfmanagement, and ongoing monitoring by the clinician.



Using the Diabetes Tool in OSCAR Pro

Using the Diabetes Menu Bar and the Summary Tabs:





Features:

- Quick action menu gives clinicians flexibility to support patient encounter needs while also keeping the patient metrics or labs or even the history window open
- Standardize data inputs captured to improve decision support within the tool as well as provide a means for evaluation
- 8 of 9 quality statements within the tool for adults who are at risk of developing prediabetes or type 2 diabetes or who already have a diagnosis of either

From the menu bar, the user has the option to:

- Review previous patient visit history
- Launch into a clinical module
- Provide tool feedback

From the Summary, the user can simultaneously:

- Update the suspected mental health condition
- View/update metrics for PHQ-9, GAD-7, WHO5, PAID
- Open the vitals flowsheet
- Filter graphing results for the previous assessments
- Review lab tests and values and launch the lab requisition form



Getting Started with the Diabetes Tool

The tool was designed to include decision support throughout the tool and has implemented tooltips, hover-overs, and pop-up windows to also help inform quality standard information.

| recommended screening frequency. | Blue text with a dotted underline – indicates hover over text. |
|----------------------------------|---|
| | Blue "i" icons – indicate hover over text. |
| Insulin initiation checklist | Blue text with a solid underline – indicates a hyperlink that will open in a new window. |
| Diabetes Canada Screening | Bolded Purple text w/a solid underline – indicates a expand/ collapsible section. Clicking this will open the section and clicking it while the section is opened will close it. |
| copy from prior | White buttons with a Yellow Outline – indicate a pop-up window. Clicking this will open the pop-up window, which will have its own close button. |
| Open consultations | White buttons with a Blue Outline – indicate a separate window for an OSCAR built-in service. |



Tool Design

There are two distinct areas of the diabetes management tool at the top we have our patient summary dashboard that includes metrics, lab results, and medical history (see below). The lower portion of the tool consists of the visit form.

Patient Summary Dashboard

The patient summary dashboard can be referenced at any point during the visit to help inform clinical decision-making or support diagnosis. The first section is first the lab section. It provides an overall summary of relevant lab results, the last date done, a visual indicator of whether it's within a specified goal range, and the ability to trend values in a graph.

At the top of this section, there are 3 action buttons that allow a user to input results manually, individualize specific goals, or insert a lab requisition.



This tool aims to address both the physical and mental well-being of diabetic patients. The demanding nature of diabetes management, the potential for serious complications, and concerns regarding hypoglycemia can all result in significant emotional strain. By prioritizing mental health support, clinicians can help mitigate the psychological burden of diabetes and improve outcomes for their patients.

The metrics section provides access to validated screeners including the PHQ-9, GAD-7, PAID, and WHO5. The first two screeners are built into the EMR, and the measurements recorded here are integrated with other tools. The latter two screeners are linked externally with the opportunity to add in results manually. All scores can be trended on a graph.

Lastly, in the patient summary dashboard section is a medical history. This section contains form-memory, so any selection or documentation from previous visits can be reviewed. The intent of the section is to support clinicians through the identification of high-risk and prediabetic patients through to diagnosis.



Launching Clinical Modules

The components related to the provision of care for diabetes and prediabetes have been broken into 4 modules, allowing for flexibility. By no means does this require all 4 modules must be completed during a visit but allows you to navigate to a module of your choosing that you would like to focus on during the encounter.

An example of the clinical assessment module is below.

Clinical Assessment Module



Screening and monitoring diabetes specific complications

• Selecting the "+" button will indicate that results are abnormal or condition present and requires follow-up.

• Selecting the "-" button will indicate that results are normal or screened but not present/no immediate action required.



Management Module

The management module supports clinicians in identifying lifestyle changes that can be taken into consideration as well as creating individual goals with the patient. To support the patient in engaging self-management strategies, related patient resources can be identified here and automatically included as part of the care plan.

Checkboxes are used to indicate if referrals have been made as well as textboxes to include any additional information. These details will also generate a note in the patient care plan to act as a reminder of the next steps. A button to open the consultations tab has been included to complete the referral if necessary.

Assessment Management Medication Patient Care Plan

Identification of patient goals and lifestyle considerations

| Management Mod | ule | copy from prior clear | last done: [2023-06-28 |
|--------------------------------|--|---|---|
| Diabetes management should be | an interactive and collaborative effo | rt between the clinician and patient. Self-management suppo | port should be person-centered, focusing on the individual's ability and resources available to them. |
| Prediabetes? Patient Goals | | | Add goal |
| Barriers to self-management Co | nsider SDoH when interacting with | patient | |
| Patient plan includes: | | | Patient Resources |
| Nutrition vap | propriate diet | discussed individualized nutrition (i) | *selected when checked |
| Physical activity 🕕 | ✓ 150 mins/week | discussed individualized plan | Mediterranean style diet - <u>link</u> |
| Weight management | discussed weight mana | gement 🕕 | DASH (Dietary Approaches to Stop Hypertension) - <u>link</u> Diabetes Canada- Healthy Eating - <u>link</u> |
| Smoking cessation | discussed progress and | methods to quit | Maintaining Aerobic Exercise - <u>link</u> |
| Sick day management | educated patients on pla | anning for sick days | Managing your smoking cessation progress - link |
| Driving guidelines | educated patients using | insulin or insulin secretagogues on driving safely | Sick Day Management - <u>link</u> Driving Safe with Diabetes - <u>link</u> Diabetes Canada- Steps to Stress Management - <u>link</u> |
| Stress management | counselled (i) | | |
| Additional notes | | | |

Referrals and next steps





Medication Module

The purpose of this module is to aid in documentation and creation of a medication plan with regularly monitoring patient adherence and response to the prescribed medications.

Medication plan also populates the patient care plan with the most recent updates to their medication plan using the dynamic table available in this module.

| Assessment Mana | gement | Medication | Patient Care | Plan |
|---|-----------------------------|------------------------------------|---------------------------------------|--|
| Medication Module | | copy from prior clear | last don | 2 [2023-06-28 |
| Prediabetes | | | | |
| In individuals with prediabetes, pharmacologic therapy with | n metformin (dosage 850 | Omg twice daily) may be used to re | educe the risk of type 2 diabetes. | |
| Care plan should include assessment of diabetogenic med medications. | lications (e.g., glucocorti | icoids and atypical antipsychotics | [olanzapine, clozapine]). If a person | s taking diabetogenic medications, weigh the risks and benefits of selecting alternative |
| Monitoring - adherence and response | | | | |
| Current medications | Medication adherent | Ce | | |
| SALBUTAMOL SULPHATE 200MCG 0 Q4H | Is medication helping | g? () Y | /es 🔘 No | |
| METFORMIN HCL 1000MG / ALOGLIPTIN BENZOATE 12 5MG 1 024H | Side effects experier | nced? | /es 💿 No | |
| | Severity of side effect | cts Mild | ~ | |

Using this medication plan section creates an ongoing list that providers can use to ensure that they are optimizing pharmacologic treatment for their patients. It makes changes made to specific medications easily viewable, by capturing the specific action done (whether that was maintaining, increasing, or decreasing a specific medication) as well as notes around that decision. Also built into this section are information tooltips and guidance for both insulin and non-insulin therapy.

Dropdown medication lists can be used to select the specific medication along with documenting any adjustments (i.e., starting a new med, discontinuing, increasing dose, decreasing dose, maintaining)

| Medication Plan <u>View medication s</u> | eference table | | | | | | | | |
|--|------------------------------|-----------------------|---------------|----------------|---------------|--------------|----------------|--------------|---------|
| Non-insulin therapy 📵 | | | | | | | | | |
| Insulin therapy 📵 | Insulin initiation checklist | | Basal insulin | | Prandial (bol | lus) insulin | | | |
| | Switching insulin | | 20% Dose red | luction method | | Unit | to-unit method | | |
| Diabetes and Cardiovascular Protein | ction | | | | | | | | |
| Statins indicated | () Yes | No | | Not prescribed | ~ | | | | |
| ACE/ARB indicated | Yes | No | | Prescribed | ~ | | | | |
| SGLT2i or GLP1-RA indicated | Yes | No | | Not prescribed | ~ | | | | |
| | | | | | | | | | |
| Dipeptidyl peptidase-4 inhibitors (D | PP4i) ~ | †Alogliptin (Nesina®) | ~ | Decreased dose | × | notes | | | |
| Add medication | | | | | | | | | |
| Insulin secretagogues-meglifinides | Repaglinid | le (Gluconorm®) Inc | reased dose | | | | | Jun 28, 2023 | \odot |
| Basal Insulin | NPH (Hurr | ulin® N) Ma | intain | | | | | Jun 28, 2023 | ⊗ |
| Prandial (bolus) insulin | Aspart (Kir | styTM) Dis | continue | | | | | Jun 28, 2023 | ⊗ |
| Dipeptidyl peptidase-4 inhibitors (DP | P4i) †Alogiptin | (Nesina®) De | creased dose | | | | | Jun 28, 2023 | \odot |

Note: This module is strictly for planning and documentation purposes and prescribing medications will still need to follow the usual workflow in OSCAR by opening the built-in medications window.



Patient Care Plan Module

Clicking on the Patient Care Plan button will open the care plan as a printable resource in another window. This can be provided to the patient as a complimentary aid to their visit.

It can be used to assist in planning the next or follow-up visit with the patient, giving you the option to document the next appointment date, plan the purpose of the appointment, review treatments and allergies, medications, and therapies.

The resources section contains a collection of curated resources for your patient and their caregivers. Clicking on the purple link will open the resource.

Both checkboxes and textboxes are embedded with form-memory that will populate the next time the form is opened by clicking Copy from prior.

| E2P | E2P Care plan | | | | |
|----------------------------------|--|----------------------------|--|-----------------------|-----------------|
| | | | copy from prior clear | last done: 2023-06-28 | |
| Care team & care conse | nt | | | | |
| Care team | | | | | |
| Coordinating lead (noti | fy if patient is hospitalized) | | Name: | Contact: | |
| Name | Role | | Organization / Address | Contact | |
| Julia Brown | Nurse | | CEP | jbrown@org.com | |
| | | | | | Add |
| Dr. Smith | Doctor | eCE | asmith@org.com | Jun 28, 2023 | \otimes |
| Julia Brown | Nurse | CEP | jbrown@org.com | Jun 28, 2023 | \otimes |
| Health care consent and | advance care planning | | | | |
| I have shared my w | vishes, values, beliefs with m | y future SDM as it relate | s to my future health care | | Submi |
| Name | Relationship | | Phone | Alternate Contact | Print |
| | | |] [|] [] | |
| | | | | | Add |
| Goals | pful to plan out you goals. Using | a plan can help give you a | sense of direction, and help you organize ar | id reach your goals. | |
| Patient Goals | | | | | |
| | | | Add goal | | |
| Lifestyle change | s & Therapy | | Allergies | | |
| 2023-05-10 ALO 1000mg once pe | GLIPTIN 12.5 MG-METFORMIN 1, r day. | 000 MG TABLET | PENTAZOCINE, PINE NUT, CODEINE | | |
| Medications | | | | | |
| Medication | Action | Notes | | | |
| | Action | ~ | | | |
| Follow-up and ne | ext steps | | | ⊕ Add | Submit Print |
| | | | | 4 | |



© 2023

Feedback

Included in the tool is a link to provide feedback which allows users to submit their thoughts and communicate any issues they've encountered or any areas they wish to see added to the tool. This section allows you to submit feedback anonymously or allows you to add your email address and name if you wish to be contacted.

The links can be found at the bottom of every module. It will look like this:

| Provide fe | eedback o | n this too | bl | |
|-----------------|----------------|----------------|-------------|---------------|
| Not satisfied | ☆ ☆ ☆ ☆ | * * * * | 📩 🕁 🕁 Ve | ery satisfied |
| Average rating | : 8.5 | | | |
| Submit a | nonymously? | | | |
| Comments: | | | | |
| Lam willin | ng to be conta | acted to prov | ide more fe | edback |
| Email: | ig to be conta | | | cubuck |
| We will never s | share your ema | il with anyone | else. | |

Overview of Usage Analytics

Please visit our website to review our overview of usage analytics.



Contact

As part of the Evidence2Practice Ontario (E2P) program, <u>Amplify</u> <u>Care</u> (formerly the eHealth Centre of Excellence) is providing change management at no cost to support clinicians with the implementation and optimal use of E2P tools.



If you have any questions, please reach out to <u>EMRtools@amplifycare.com</u> and we will be happy to help!

E2P brings together multi-disciplinary, cross-sector expertise under the joint leadership of the <u>Centre for</u> <u>Effective Practice</u>, <u>Amplify Care</u>, and <u>North York General Hospital</u>. Funding and strategic guidance for E2P is provided by Ontario Health in support of Ontario's Digital First for Health Strategy





Appendix

Quality Standards for Diabetes

The E2P diabetes tool components address care for adults who have various types of diabetes, including the assessment and diagnosis of people who are suspected of having diabetes. It applies to community settings, including primary care, specialist care, home care, hospital outpatient clinics, and long-term care.

- 1. Screening for Risk Factors and Testing for Prediabetes and Type 2 Diabetes
 - a. Clinical assessment
- 2. Reducing the Risk of Type 2 Diabetes
 - a. Supplemental provider education / support
- 3. Identifying and Assessing Mental Health Needs
 - a. Ongoing monitoring
- 4. Healthy Behaviour Changes
- 5. Setting and Achieving Glycemic Targets
 - a. Clinical assessment
- 6. Access to a Collaborative Interprofessional Care Team
- 7. Promoting Self-Management Skills
 - a. Patient Care Plan
- 8. Screening for Complications and Risk Factors
 - a. Clinical assessment
- 9. Cardiovascular Protection